Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals
These two companies are going after the same target, but which one should you bet on today?
Madrigal Pharmaceuticals, Inc.(MDGL)
Nasdaq Capital Market (Nasdaq)
MDGL
$117.48
-$3.71
-3.1%
Price as of March 1, 2021, 7:50 p.m. EST
View Interactive MDGL Charts
Madrigal Pharmaceuticals, Inc.
Interactive Chart
News & Analysis: Madrigal Pharmaceuticals, Inc.
3 Top Biotech Stocks to Buy in June
They have one big thing in common: great growth prospects.
Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals
These companies are developing drugs that target the one of the biggest threats from the obesity epidemic.
3 Things to Watch From the Pharmaceutical Industry's Liver Meeting
Investors will want to pay attention to what Assembly Biosciences, CymaBay Therapeutics, and Madrigal Pharmaceuticals say about their most promising candidate therapies.
Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals
Which of these NASH-oriented biotechs is the better buy?
3 Beaten-Down Biotech Stocks That Could Bounce Back in 2019
A new year and reasons to remain hopeful for these three biotechs are around the corner.
Here's Why Madrigal Pharmaceuticals Fell 39.4% in November
Impressive results from a potential competitor took the shine off this biotech's experimental NASH treatment.
Why Madrigal Pharmaceuticals Stock Slumped in October
Madrigal's stock continued to cool off last month, but another rally could be close at hand.
Better Buy: Intercept Pharmaceuticals Inc. vs. Madrigal Pharmaceuticals
Which stock wins in a matchup between these biotechs hoping for success with promising NASH drugs?
Here's Why Viking Therapeutics Skyrocketed 33% in September
Solid phase 2 data has investors excited about the biotech's future.
